| GTO ID | GTC3070 |
| Trial ID | NCT05417126 |
| Disease | Stargardt Disease |
| Altered gene | MCO |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | vMCO-010 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease |
| Year | 2022 |
| Country | United States |
| Company sponsor | Nanoscope Therapeutics Inc. |
| Other ID(s) | NTXMCO-004 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||
|
|||||||||